Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression: A Raclopride/F-DOPA PET and fMRI Study
Reference Number: 201106402
WHAT IS THE PURPOSE OF THE STUDY?
The purpose of the study is to help understand why adding aripiprazole (a type of antidepressant) combined with another antidepressant is effective in people who have treatment resistant depression.
WHO IS NEEDED?
1. Volunteers age 18-55
2. Volunteers must have a diagnosis of depression.
3. Volunteers must have not responded to at least one previous antidepressant
4. Volunteers must not have schizophrenia, bipolar disorder, or anxiety disorder
WHAT IS INVOLVED IF I PARTICIPATE?
Duration: The study will last 18 weeks including follow-up. There will be 10 outpatient visits. Eight of the ten visits will last 60-90 minutes, the other two visits will last about 6 hours.
Tests/Procedures: Blood tests, urine drug screen, ECG, psychological assessments, 2 MRIs and 4 PET scans.
Risks: Risks will be discussed with volunteers as part of the informed consent process.
Benefits: All antidepressant medication will be provided at no cost to qualified volunteers for 16 weeks.
Compensation: Up to $550 is provided for time and effort.
WHO IS THE PRINCIPAL INVESTIGATOR (DOCTOR)?
Charles Conway, MD
WHERE WILL THE STUDY TAKE PLACE?
Washington University School of Medicine
Martha Cornell, RN